Investment Analysis of Regeneron Pharmaceuticals Inc (REGN)

REGN April 28, 2025 By Brad

Investment Thesis Buy

Investment Criteria
Anticipated Hold Period:

Medium-term (1-3 years)

Investment Amount

$833

Decision

Buy

Conviction Level

Low - Took a flyer on this division. Worst case, we shut it down and blame the interns.

Your Share of Net Income

$61.50

Competitive Analysis
Competitive Advantage

No competitive advantage analysis provided.

Key Non-Financial Metrics

No key metrics provided.

Net Income Projections
Net Income
CAGR: 20.8%
Analyst Notes:

No comments provided by the analyst.

Dividends
Analyst Notes:

No comments provided by the analyst.

Payout Ratio
Analyst Notes:

No comments provided by the analyst.

Revenue
CAGR: 12.7%
Analyst Notes:

No comments provided by the analyst.

Avg Annual Growth Rate (10Y)
Analyst Notes:

No comments provided about CAGR comparison.

Balance Sheet Cash
CAGR: 14.8%
Analyst Notes:

No comments provided by the analyst.

Debt
CAGR: 17.9%
Analyst Notes:

No comments provided by the analyst.

Free Cash Flow
CAGR: 18.4%
Analyst Notes:

No comments provided by the analyst.

Cash Flow from Operations
CAGR: 12.2%
Analyst Notes:

No comments provided by the analyst.

Comments

Log in to leave a comment.
0 Comments

No comments yet. Be the first to comment!